Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$73.22 USD

73.22
407,321

-0.74 (-1.00%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $73.21 -0.01 (-0.01%) 5:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Align Technology (ALGN) Moves 11.1% Higher: Will This Strength Last?

Align Technology (ALGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Conmed (CNMD) Up 14.3% Since Last Earnings Report: Can It Continue?

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

CNMD or ALGN: Which Is the Better Value Stock Right Now?

CNMD vs. ALGN: Which Stock Is the Better Value Option?

CONMED (CNMD) Beats on Q3 Earnings, Ups '23 EPS View

CONMED's (CNMD) adjusted third-quarter earnings and sales beat estimates on the back of strong growth in the U.S and international markets. Gross margin improves.

Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Conmed (CNMD) Q3 Earnings and Revenues Surpass Estimates

Conmed (CNMD) delivered earnings and revenue surprises of 8.43% and 1.12%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.

Here's Why You Should Add McKesson (MCK) to Your Portfolio

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

CNMD vs. ALGN: Which Stock Is the Better Value Option?

CNMD vs. ALGN: Which Stock Is the Better Value Option?

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?

Here is how Boston Scientific (BSX) and Conmed (CNMD) have performed compared to their sector so far this year.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Is a Beat Likely for Cooper Companies (COO) in Q3 Earnings?

Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.

Is a Beat Likely for Patterson Companies (PDCO) in Q1 Earnings?

Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at both Dental and Animal Health segments.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

CONMED (CNMD) Beats on Q2 Earnings, Ups '23 EPS View

CONMED's (CNMD) adjusted second-quarter earnings and sales recover from the disruption in the last two quarters due to implementation of a new warehouse management system.

Conmed (CNMD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates

Conmed (CNMD) delivered earnings and revenue surprises of 5.06% and 3.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

Patterson Companies (PDCO) Q4 Earnings Beat, Sales Hurt by FX

Patterson Companies' (PDCO) fiscal fourth-quarter 2023 results reflect robust improvement in Dental Equipment sales, Value-added services and Animal Health segment.

Here's Why You Should Retain Insulet (PODD) Stock for Now

Investors are optimistic about Insulet (PODD) owing to strength in Omnipod 5 and its focus on market expansion.

Align's (ALGN) Invisalign Sales Grow Globally Amid Margin Woe

Align (ALGN) is confident about a largely untapped market opportunity for digital orthodontics and restorative dentistry.

Orthofix (OFIX) Advances in ALIF Procedure With New Launch

Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.